Evaxion Biotech AS
Company Profile
Business description
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are: EVX-01, EVX-03, and EVX-02, which are vaccine candidates being developed for the treatment of various solid cancers. In addition, the company is developing EVX-B1, EVX-B2, EVX-B3, EVX-V1, and multiple other vaccine candidates for various infectious diseases, such as cytomegalovirus, N.gonorrhoeae, bacterial pathogens, and others.
Contact
Dr. Neergaards Vej 5f
Hoersholm2970
DNKT: +45 31319753
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
46
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,462.60 | 40.90 | 0.49% |
CAC 40 | 7,743.75 | 49.31 | 0.64% |
DAX 40 | 23,499.32 | 146.63 | 0.63% |
Dow JONES (US) | 41,249.38 | 119.07 | -0.29% |
FTSE 100 | 8,554.80 | 23.19 | 0.27% |
HKSE | 22,867.74 | 91.82 | 0.40% |
NASDAQ | 17,928.92 | 0.78 | 0.00% |
Nikkei 225 | 37,503.33 | 574.70 | 1.56% |
NZX 50 Index | 12,605.07 | 138.04 | 1.11% |
S&P 500 | 5,659.91 | 4.03 | -0.07% |
S&P/ASX 200 | 8,231.20 | 39.50 | 0.48% |
SSE Composite Index | 3,342.00 | 10.00 | -0.30% |